

# PRODUCT INFORMATION




## Anacetrapib

Item No. 21558

**CAS Registry No.:** 875446-37-0  
**Formal Name:** (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-2'-methoxy-5'-(1-methylethyl)-4-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-4-methyl-2-oxazolidinone

**Synonym:** MK-0859  
**MF:** C<sub>30</sub>H<sub>25</sub>F<sub>10</sub>NO<sub>3</sub>  
**FW:** 637.5  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 255, 285 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Anacetrapib is supplied as a crystalline solid. A stock solution may be made by dissolving the anacetrapib in the solvent of choice, which should be purged with an inert gas. Anacetrapib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of anacetrapib in ethanol and DMF is approximately 30 mg/ml and approximately 20 mg/ml in DMSO.

Anacetrapib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, anacetrapib should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Anacetrapib has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Anacetrapib is an inhibitor of cholesterol ester transfer protein (CETP) with IC<sub>50</sub> values of 17 and 15 nM for CETP-dependent transfer of cholesterol esters and triglycerides, respectively.<sup>1</sup> It decreases plasma levels of LDL and triglycerides, reduces atherosclerotic lesion sizes, and increases HDL levels in the E3L.CETP mouse model of atherosclerosis.<sup>2</sup> Anacetrapib (150 mg/kg) increases HDL levels by 2-fold and lowers LDL and fasting plasma triglyceride levels in rhesus macaques.<sup>3</sup>

### References

1. Ranalletta, M., Bierilo, K.K., Chen, Y., *et al.* Biochemical characterization of cholesteryl ester transfer protein inhibitors. *J. Lipid Res.* **51(9)**, 2739-2752 (2010).
2. van der Tuin, S.J., Kühnast, S., Berbée, J.F., *et al.* Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. *J. Lipid Res.* **56(11)**, 2085-2093 (2015).
3. McLaren, D.G., Previs, S.F., Phair, R.D., *et al.* Evaluation of CETP activity in vivo under non-steady-state conditions: Influence of anacetrapib on HDL-TG flux. *J. Lipid Res.* **57(3)**, 398-409 (2016).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/18/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM